Specific immunotherapy of experimental myasthenia by genetically engineered APCs

The "guided missile" strategy

D. B. Drachman, J. M. Wu, A. Miagkov, M. A. Williams, R. N. Adams, B. Wu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Although treatment of MG with general immunosuppressive agents is often effective, it has important drawbacks, including suppression of the immune system as a whole, with the risks of infection and neoplasia, and numerous other adverse side effects. Ideally, treatment of MG should eliminate the specific pathogenic autoimmune response to AChR, without otherwise suppressing the immune system or producing other adverse side effects. Although antibodies to AChR are directly responsible for the loss of AChRs at neuromuscular junctions in MG, the AChR antibody response is T cell-dependent, and immunotherapy directed at T cells can abrogate the autoantlbody response, with resulting benefit. As in other autoimmune diseases, the T cell response in MG is highly heterogeneous. The design of specific immunotherapy must take this heterogeneity into account and target the entire repertoire of AChR-specific T cells. We describe our investigation of a novel strategy for specific immunotherapy of MG, involving gene transfer to convert antigen-presenting cells (APCs) to "guided missiles" that target AChR-specific T cells, and that induce apoptosis and elimination of those T cells. This strategy uses the ability of APCs from a given individual to present the entire spectrum of AChR epltopes unique for that individual, and thereby to target the entire repertoire of antigen-specific T cells of the same individual. Using viral vectors, we have genetically engineered the APCs to process and present the most important domain of the AChR molecule, and to express a "warhead" of Fas ligand (FasL) to eliminate the activated AChR-specific T cells with which they interact. Our results show that the APCs express the appropriate gene products, and effectively and specifically eliminate AChR-specific T cells by the Fas/FasL pathway, while sparing T cells of other specificities.

Original languageEnglish (US)
Pages (from-to)520-532
Number of pages13
JournalAnnals of the New York Academy of Sciences
Volume998
DOIs
StatePublished - 2003

Fingerprint

Autoimmune Experimental Myasthenia Gravis
Guided missiles
T-cells
Antigen-Presenting Cells
Immunotherapy
T-Lymphocytes
Fas Ligand Protein
Immune system
Immune System
T-Cell Antigen Receptor Specificity
Cells
Gene transfer
Neuromuscular Junction
Immunosuppressive Agents
Antibodies
Autoimmunity
Genes
Autoimmune Diseases
Antibody Formation
Apoptosis

Keywords

  • "guided missiles"
  • Experimental myasthenia gravis
  • Fas ligand
  • Genetically engineered APCs
  • Specific immunotherapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Specific immunotherapy of experimental myasthenia by genetically engineered APCs : The "guided missile" strategy. / Drachman, D. B.; Wu, J. M.; Miagkov, A.; Williams, M. A.; Adams, R. N.; Wu, B.

In: Annals of the New York Academy of Sciences, Vol. 998, 2003, p. 520-532.

Research output: Contribution to journalArticle

Drachman, D. B. ; Wu, J. M. ; Miagkov, A. ; Williams, M. A. ; Adams, R. N. ; Wu, B. / Specific immunotherapy of experimental myasthenia by genetically engineered APCs : The "guided missile" strategy. In: Annals of the New York Academy of Sciences. 2003 ; Vol. 998. pp. 520-532.
@article{a1dac9499cf9453b80b159f408ec0cd1,
title = "Specific immunotherapy of experimental myasthenia by genetically engineered APCs: The {"}guided missile{"} strategy",
abstract = "Although treatment of MG with general immunosuppressive agents is often effective, it has important drawbacks, including suppression of the immune system as a whole, with the risks of infection and neoplasia, and numerous other adverse side effects. Ideally, treatment of MG should eliminate the specific pathogenic autoimmune response to AChR, without otherwise suppressing the immune system or producing other adverse side effects. Although antibodies to AChR are directly responsible for the loss of AChRs at neuromuscular junctions in MG, the AChR antibody response is T cell-dependent, and immunotherapy directed at T cells can abrogate the autoantlbody response, with resulting benefit. As in other autoimmune diseases, the T cell response in MG is highly heterogeneous. The design of specific immunotherapy must take this heterogeneity into account and target the entire repertoire of AChR-specific T cells. We describe our investigation of a novel strategy for specific immunotherapy of MG, involving gene transfer to convert antigen-presenting cells (APCs) to {"}guided missiles{"} that target AChR-specific T cells, and that induce apoptosis and elimination of those T cells. This strategy uses the ability of APCs from a given individual to present the entire spectrum of AChR epltopes unique for that individual, and thereby to target the entire repertoire of antigen-specific T cells of the same individual. Using viral vectors, we have genetically engineered the APCs to process and present the most important domain of the AChR molecule, and to express a {"}warhead{"} of Fas ligand (FasL) to eliminate the activated AChR-specific T cells with which they interact. Our results show that the APCs express the appropriate gene products, and effectively and specifically eliminate AChR-specific T cells by the Fas/FasL pathway, while sparing T cells of other specificities.",
keywords = "{"}guided missiles{"}, Experimental myasthenia gravis, Fas ligand, Genetically engineered APCs, Specific immunotherapy",
author = "Drachman, {D. B.} and Wu, {J. M.} and A. Miagkov and Williams, {M. A.} and Adams, {R. N.} and B. Wu",
year = "2003",
doi = "10.1196/annals.1254.068",
language = "English (US)",
volume = "998",
pages = "520--532",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Specific immunotherapy of experimental myasthenia by genetically engineered APCs

T2 - The "guided missile" strategy

AU - Drachman, D. B.

AU - Wu, J. M.

AU - Miagkov, A.

AU - Williams, M. A.

AU - Adams, R. N.

AU - Wu, B.

PY - 2003

Y1 - 2003

N2 - Although treatment of MG with general immunosuppressive agents is often effective, it has important drawbacks, including suppression of the immune system as a whole, with the risks of infection and neoplasia, and numerous other adverse side effects. Ideally, treatment of MG should eliminate the specific pathogenic autoimmune response to AChR, without otherwise suppressing the immune system or producing other adverse side effects. Although antibodies to AChR are directly responsible for the loss of AChRs at neuromuscular junctions in MG, the AChR antibody response is T cell-dependent, and immunotherapy directed at T cells can abrogate the autoantlbody response, with resulting benefit. As in other autoimmune diseases, the T cell response in MG is highly heterogeneous. The design of specific immunotherapy must take this heterogeneity into account and target the entire repertoire of AChR-specific T cells. We describe our investigation of a novel strategy for specific immunotherapy of MG, involving gene transfer to convert antigen-presenting cells (APCs) to "guided missiles" that target AChR-specific T cells, and that induce apoptosis and elimination of those T cells. This strategy uses the ability of APCs from a given individual to present the entire spectrum of AChR epltopes unique for that individual, and thereby to target the entire repertoire of antigen-specific T cells of the same individual. Using viral vectors, we have genetically engineered the APCs to process and present the most important domain of the AChR molecule, and to express a "warhead" of Fas ligand (FasL) to eliminate the activated AChR-specific T cells with which they interact. Our results show that the APCs express the appropriate gene products, and effectively and specifically eliminate AChR-specific T cells by the Fas/FasL pathway, while sparing T cells of other specificities.

AB - Although treatment of MG with general immunosuppressive agents is often effective, it has important drawbacks, including suppression of the immune system as a whole, with the risks of infection and neoplasia, and numerous other adverse side effects. Ideally, treatment of MG should eliminate the specific pathogenic autoimmune response to AChR, without otherwise suppressing the immune system or producing other adverse side effects. Although antibodies to AChR are directly responsible for the loss of AChRs at neuromuscular junctions in MG, the AChR antibody response is T cell-dependent, and immunotherapy directed at T cells can abrogate the autoantlbody response, with resulting benefit. As in other autoimmune diseases, the T cell response in MG is highly heterogeneous. The design of specific immunotherapy must take this heterogeneity into account and target the entire repertoire of AChR-specific T cells. We describe our investigation of a novel strategy for specific immunotherapy of MG, involving gene transfer to convert antigen-presenting cells (APCs) to "guided missiles" that target AChR-specific T cells, and that induce apoptosis and elimination of those T cells. This strategy uses the ability of APCs from a given individual to present the entire spectrum of AChR epltopes unique for that individual, and thereby to target the entire repertoire of antigen-specific T cells of the same individual. Using viral vectors, we have genetically engineered the APCs to process and present the most important domain of the AChR molecule, and to express a "warhead" of Fas ligand (FasL) to eliminate the activated AChR-specific T cells with which they interact. Our results show that the APCs express the appropriate gene products, and effectively and specifically eliminate AChR-specific T cells by the Fas/FasL pathway, while sparing T cells of other specificities.

KW - "guided missiles"

KW - Experimental myasthenia gravis

KW - Fas ligand

KW - Genetically engineered APCs

KW - Specific immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=0043247144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043247144&partnerID=8YFLogxK

U2 - 10.1196/annals.1254.068

DO - 10.1196/annals.1254.068

M3 - Article

VL - 998

SP - 520

EP - 532

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -